Last reviewed · How we verify
Ocaliva — Competitive Intelligence Brief
phase 2
G-protein coupled bile acid receptor 1, Bile acid receptor
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Ocaliva (Ocaliva) — Universitaire Ziekenhuizen KU Leuven.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ocaliva TARGET | Ocaliva | Universitaire Ziekenhuizen KU Leuven | phase 2 | G-protein coupled bile acid receptor 1, Bile acid receptor | ||
| Cholbam | Cholbam | Mirum Pharmaceuticals, Inc. | marketed | G-protein coupled bile acid receptor 1, Bile acid receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Ocaliva — Competitive Intelligence Brief. https://druglandscape.com/ci/ocaliva. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing